Makhnoon Sukh, Lee MinJae, Prasad Tanushree, Badalamenti Alexa, Gurley Tami, Waters Erika A, Skinner Celette Sugg
Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Front Genet. 2024 Nov 8;15:1462831. doi: 10.3389/fgene.2024.1462831. eCollection 2024.
Awareness, access, and use of clinical and direct-to-consumer (DTC) genetic tests has increased in recent years with documented disparities in these services. We provide updated data on test awareness and use, and report novel data on motivations and methods for accessing genetic tests.
Nationally representative data from the 2022 Health Information National Trends Survey (HINTS 6) were used to assess awareness and use of ancestry, personal trait, specific disease, and carrier testing by sociodemographic characteristics, examine reasons for undergoing tests, and methods of accessing them.
Overall, 81.4% of respondents were aware and 40.0% had undergone testing. Only 10% of tests were ordered by genetic counselors, 80% of carrier and 65% of specific disease tests were ordered by other healthcare providers. Understanding family history was the most common reason for undergoing ancestry (72.2%) or personal trait tests (64.9%) whereas reasons such as doctor's recommendation (53%-59%), learning more about disease risk (18%-50%), and carrier testing (76%) were common for undergoing disease risk tests and carrier tests. In contrast to ancestry, personal trait, and carrier testing, there were no racial, ethnic, income, or rural/urban difference in use of specific disease risk testing.
Diffusion of genetic tests into US society, although incremental, has made sizable increases in awareness, equitable use of specific disease tests but worsening socioeconomic inequality in DTC genetic test use. The study provides update on the state of genetic testing in the US and identifies groups that may need help accessing clinical genomic information and services.
近年来,临床基因检测和直接面向消费者(DTC)的基因检测的知晓度、可及性和使用率有所提高,且这些服务存在已记录在案的差异。我们提供了有关检测知晓度和使用率的最新数据,并报告了有关获取基因检测的动机和方法的新数据。
使用来自2022年全国健康信息趋势调查(HINTS 6)的具有全国代表性的数据,按社会人口统计学特征评估对血统、个人特质、特定疾病和携带者检测的知晓度和使用率,研究进行检测的原因以及获取检测的方法。
总体而言,81.4%的受访者知晓基因检测,40.0%的受访者进行过检测。只有10%的检测是由遗传咨询师开出的,80%的携带者检测和65%的特定疾病检测是由其他医疗服务提供者开出的。了解家族病史是进行血统检测(72.2%)或个人特质检测(64.9%)最常见的原因,而诸如医生推荐(53%-59%)、更多了解疾病风险(18%-50%)和携带者检测(76%)等原因是进行疾病风险检测和携带者检测的常见原因。与血统、个人特质和携带者检测不同,在使用特定疾病风险检测方面不存在种族、民族、收入或城乡差异。
基因检测在美国社会的传播虽然是渐进的,但在知晓度方面有了大幅提高,特定疾病检测的使用更加公平,但DTC基因检测使用中的社会经济不平等却在加剧。该研究提供了美国基因检测状况的最新情况,并确定了可能需要帮助以获取临床基因组信息和服务的群体。